Arcutis Biotherapeutics Inc (ARQT)vsEli Lilly and Company (LLY)
ARQT
Arcutis Biotherapeutics Inc
$23.89
+2.16%
HEALTHCARE · Cap: $3.00B
LLY
Eli Lilly and Company
$1,137.76
+1.98%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 17070% more annual revenue ($79.67B vs $463.98M). LLY leads profitability with a 33.5% profit margin vs 6.2%. LLY trades at a lower P/E of 37.7x. LLY earns a higher WallStSmart Score of 76/100 (B+).
ARQT
Hold47
out of 100
Grade: D+
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+80.2%
Fair Value
$134.15
Current Price
$23.89
$110.27 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 59.3% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
Trading at 13.6x book value
0.0% earnings growth
6.2% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ARQT
The strongest argument for ARQT centers on Revenue Growth. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : ARQT
The primary concerns for ARQT are Price/Book, EPS Growth, Profit Margin. A P/E of 108.6x leaves little room for execution misses.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
ARQT profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
ARQT carries more volatility with a beta of 1.50 — expect wider price swings.
ARQT is growing revenue faster at 59.3% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 47/100), backed by strong 33.5% margins and 47.7% revenue growth. ARQT offers better value entry with a 80.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arcutis Biotherapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company is headquartered in Westlake Village, California.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?